Institution
University of Lorraine
Education•Nancy, France•
About: University of Lorraine is a education organization based out in Nancy, France. It is known for research contribution in the topics: Population & Context (language use). The organization has 11942 authors who have published 25010 publications receiving 425227 citations. The organization is also known as: Lorraine University.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: A preliminary set of criteria that could be used to classify IBD disease severity is proposed and it is suggested that a disease severity classification should be developed and validated by an international group to develop a pragmatic means of identifying patients with severe disease.
278 citations
••
TL;DR: The work at NUI Galway was supported by Saudi Aramco under the FUELCOM program as discussed by the authors, and the collaboration between NUIGalway and LRGP entered in the frame the COST Action CM1404.
276 citations
••
TL;DR: The benefits of SGLT2 inhibitors in heart failure may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption, which has important implications for the design and analysis of large-scale outcomes trials involving diabetic or nondiabetic patients with chronic heart failure.
Abstract: Importance Only 1 class of glucose-lowering agents—sodium-glucose cotransporter 2 (SGLT2) inhibitors—has been reported to decrease the risk of cardiovascular events primarily by reducing the risk of the development or progression of heart failure. In a landmark trial called Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes [EMPA-REG Outcomes], long-term treatment with empagliflozin prevented fatal and nonfatal heart failure events but did not reduce the risk of myocardial infarction or stroke in diabetic patients. Observations The beneficial effect of SGLT2 inhibitors on heart failure cannot be explained by their actions on glycemic control or as osmotic diuretics. Instead, in the kidneys, SGLT2 functionally interacts with the sodium-hydrogen exchanger, which is responsible for the majority of sodium tubular reuptake following filtration. The activity of sodium-hydrogen exchanger is markedly increased in patients with heart failure and may be responsible for both resistance to diuretics and to endogenous natriuretic peptides. In addition, in the heart, empagliflozin appears to inhibit sodium-hydrogen exchange, which may in turn lead to a reduction in cardiac injury, hypertrophy, fibrosis, remodeling, and systolic dysfunction. Furthermore, the major pathophysiological derangements of heart failure and a preserved ejection fraction may be mitigated by the actions of SGLT2 inhibitors to reduce blood pressure, body weight, and fluid retention as well as to improve renal function. The benefits of spironolactone in patients with heart failure with either a reduced or a preserved ejection fraction may also be attributable to the actions of the drug to inhibit the sodium-hydrogen exchange mechanism. Conclusions and Relevance The benefits of SGLT2 inhibitors in heart failure may be mediated by the inhibition of sodium-hydrogen exchange rather than the effect on glucose reabsorption. This hypothesis has important implications for the design and analysis of large-scale outcomes trials involving diabetic or nondiabetic patients with chronic heart failure.
275 citations
••
11 May 2014TL;DR: This article proposes another heuristic algorithm that provides a quasi-polynomial complexity when q is of size at most comparable with k, and for larger values of q that stay below the limit \(L_{q^k}(1/3)\), this algorithm loses its quasi- polynomial nature, but still surpasses the Function Field Sieve.
Abstract: The difficulty of computing discrete logarithms in fields \(\mathbb{F}_{q^k}\) depends on the relative sizes of k and q. Until recently all the cases had a sub-exponential complexity of type L(1/3), similar to the factorization problem. In 2013, Joux designed a new algorithm with a complexity of L(1/4 + e) in small characteristic. In the same spirit, we propose in this article another heuristic algorithm that provides a quasi-polynomial complexity when q is of size at most comparable with k. By quasi-polynomial, we mean a runtime of n O(logn) where n is the bit-size of the input. For larger values of q that stay below the limit \(L_{q^k}(1/3)\), our algorithm loses its quasi-polynomial nature, but still surpasses the Function Field Sieve. Complexity results in this article rely on heuristics which have been checked experimentally.
270 citations
••
University of Texas Health Science Center at San Antonio1, Georgia Regents University2, Vancouver Island Health Authority3, University of Rennes4, University of Lorraine5, University of California, Davis6, Monash University7, Tulane University8, Uppsala University9, University of Gothenburg10, Merck & Co.11
TL;DR: The C-WORTHY trial as mentioned in this paper was a randomized, open-label phase 2 trial of grazoprevir plus elbasvir with or without ribavirin in patients with hepatitis C virus (HCV) genotype 1 infection with baseline characteristics of poor response.
269 citations
Authors
Showing all 12161 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jonathan I. Epstein | 138 | 1121 | 80975 |
Peter Tugwell | 129 | 948 | 125480 |
David Brown | 105 | 1257 | 46827 |
Faiez Zannad | 103 | 839 | 90737 |
Sabu Thomas | 102 | 1554 | 51366 |
Francis Martin | 98 | 733 | 43991 |
João F. Mano | 97 | 822 | 36401 |
Jonathan A. Epstein | 94 | 299 | 27492 |
Muhammad Imran | 94 | 3053 | 51728 |
Laurent Peyrin-Biroulet | 90 | 901 | 34120 |
Athanase Benetos | 83 | 391 | 31718 |
Michel Marre | 82 | 444 | 39052 |
Bruno Rossion | 80 | 337 | 21902 |
Lyn March | 78 | 367 | 62536 |
Alan J. M. Baker | 76 | 234 | 26080 |